ArticleJAMA otolaryngology-- head & neck surgery2018
Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer.
Article in JAMA otolaryngology-- head & neck surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Diagnostic Efficiency of Thyroglobulin in Lymph Node Fine-needle Aspiration Washout: A Systematic Review and Meta-analysis.The Journal of clinical endocrinology and metabolism · 2025Pooled it
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- Pre-ablation stimulated thyroglobulin to TSH ratio as a strong predictor of non-generally satisfactory response to initial radioiodine therapy in papillary thyroid carcinoma patients undergoing lateral neck dissection.Annals of medicine · 2026Article
- Intermediate risk thyroid cancer management: physician survey.Journal of the Endocrine Society · 2026Article
- Prognostic value of FNA-Tg for local recurrence following lateral neck dissection in papillary thyroid carcinoma.BMC endocrine disorders · 2026Article
- Lymph-node ratio for micropapillary and nonmicropapillary differentiated thyroid cancers: a comprehensive analysis.Updates in surgery · 2025Article
- Predictive factors for failure in patients with N1b papillary thyroid carcinoma.World journal of surgical oncology · 2025Article
- A Deep Learning Survival Model for Evaluating the Survival Prognosis of Papillary Thyroid Cancer: A Population-Based Cohort Study.Annals of surgical oncology · 2025Article
- Pathological metastatic lymph node density (ND) predicts early recurrence in papillary thyroid cancer patients after curative resection.Gland surgery · 2025Article
- Prognostic value of positive lymph node ratio in oral cavity squamous cell carcinoma after neoadjuvant treatment: a retrospective real-world study.Scientific reports · 2025Article
- A nomogram based on the 3-gene signature and clinical characteristics for predicting lymph node metastasis in papillary thyroid cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Association of Lymph Nodes Positive Rate With the Risk of Recurrence in Patients With Stage T1 Papillary Thyroid Cancer.Journal of the Endocrine Society · 2024Article
- Status of mental and social activities of young and middle-aged patients after papillary thyroid cancer surgery.Frontiers in oncology · 2024Article
- Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis.Frontiers in endocrinology · 2024Article
- Single-center external validation and reconstruction of multiple predictive models for skip lateral lymph node metastasis in papillary thyroid carcinoma.Frontiers in endocrinology · 2024Article
- The impact of lymph node ratio on disease recurrence in papillary thyroid microcarcinoma.Annals of the Royal College of Surgeons of England · 2023Article
- Analysis of factors associated with the prognosis of papillary thyroid cancer and the construction of a survival model.Cancer medicine · 2023Article
- Prognostic value of lymph node density on cancer staging system for gastric cancer without distal metastasis: a population-based analysis of SEER database.World journal of surgical oncology · 2022Article
- Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma.BMC surgery · 2022Article
- Long-Term Survival in Patients With Papillary Thyroid Cancer Who Did Not Undergo Prophylactic Central Lymph Node Dissection: A SEER-Based Study.World journal of oncology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Lymph node metastases are common in papillary thyroid cancer (PTC), yet the impact of nodal metastases on survival remains unclear. Lymph node density (LND) is the ratio between the number of positive lymph nodes excised and the total number of excised lymph nodes. Lymph node density has been suggested as a prognostic factor in many types of cancer. Objective: To evaluate the prognostic role of LND in PTC. Design, Setting, and Participants: This cohort study reviewed medical records of patients with PTC who were treated at the University of Texas MD Anderson Cancer Center between January 1, 2000, and December 31, 2015. Survival and recurrence outcomes were calculated by using the Kaplan-Meier method. Significant variables on univariate analysis were subjected to a Cox proportional hazards regression multivariate model. Main Outcomes and Measures: Primary study outcome was disease-specific survival (DSS); other measurements included overall survival (OS). Results: The study cohort included data for 2542 patients (1801 [71%] male; median age, 48 years [range, 18-97 years]) with a median follow-up of 55 months (range, 4-192 months). The 10-year disease-specific survival rate was 98% for patients with LND of 0.19 or less, compared with 90% for those with LND greater than 0.19 (effect size, 8%; 95% CI, 4%-15%). The 10-year overall survival was 87% for patients with LND of 0.19 or less, compared with 79% for patients with LND greater than 0.19 (effect size, 8%; 95% CI, 3%-15%). Multivariable analysis revealed that LND greater than 0.19 was independently associated with an adverse DSS (hazard ratio [HR], 4.11; 95% CI, 2.11-8.97) and OS (HR, 1.96; 95% CI, 1.24-4.11). Subgroup analysis of patients with 18 or more lymph nodes analyzed revealed that LND greater than 0.19 remained a significant marker for DSS (HR, 2.94; 95% CI, 1.36-9.81) and OS (HR, 2.26; 95% CI, 1.12-5.34). Incorporating LND into the current American Joint Committee on Cancer staging system successfully stratified risk groups compared with the traditional TNM staging system. Conclusions and Relevance: This single-institute study demonstrates the reproducibility of LND as a predictor of outcomes in PTC. Lymph node density can potentially assist in identifying patients with poorer survival who may benefit from more aggressive adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.